Abstract
BackgroundSpecial AT rich sequence binding protein 1 (SATB1) plays a crucial role in the biology of various types of human cancer. However, the role of SATB1 in human nasopharyngeal carcinoma (NPC) remains unknown. In the present study, we sought to investigate the contribution of aberrant SATB1 expression in the progression of NPC and its association with the Epstein Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1).MethodsImmunohistochemical analysis was performed to detect SATB1 and LMP-1 protein in clinical samples, and the association of SATB1 protein expression with patient clinicopathological characteristics and LMP-1 expression were analyzed. SATB1 expression profiles were evaluated in well-differentiated NPC cell line CNE1, poorly-differentiated CNE2Z, undifferentiated C666-1 and immortalized nasopharyngeal epithelia NP-69 cells using quantitative RT-PCR, western blotting and fluorescent staining. After inhibition the SATB1 expression by using SATB1 specific small interfering RNA in these cell lines, the change of cell proliferation was investigated by western blotting analysis of PCNA (proliferating cell nuclear antigen) expression and CCK-8 assay, and the cell migration was assessed by Transwell migration assay. Finally, the expressions of SATB1 and PCNA were examined in CNE1 cells that forced LMP-1 expression by fluorescent staining and RT-PCR.ResultsImmunohistochemical analysis revealed that SATB1 protein expression was elevated in NPC tissues compared to benign nasopharyngeal tissues (P = 0.005). Moreover, high levels of SATB1 protein expression were positively correlated with clinical stage (P = 0.025), the status of lymph node metastasis (N classification) (P = 0.018), distant metastasis (M classification) (P = 0.041) and LMP-1 expression status (r = 2.35, P < 0.01) in NPC patients. In vitro experiments demonstrated that an inverse relationship between SATB1 expression and NPC differentiation status, with SATB1 weakly expressed in NP-69 cells and CNE1 cells, and significant increasingly expressed in CNE-2Z and C666-1 cells. Targeted knockdown of SATB1 expression obviously attenuated the proliferation and migration of highly SATB1-expressing CNE2Z and C666-1 cells, but not NP-69 and CNE1 cells. Interestingly, forced LMP-1 expression in CNE1 cells led to a surprisingly increasing SATB1 expression and nuclear location, companying with an up-regulated PCNA expression.ConclusionsOur results reveal that EBV LMP-1-mediated over-expression of SATB1 is associated with NPC progression, suggesting SATB1 may represent a promising biomarker and therapeutic target for NPC.
Highlights
Special AT rich sequence binding protein 1 (SATB1) plays a crucial role in the biology of various types of human cancer
Our results reveal that Epstein Barr virus (EBV) latent membrane protein 1 (LMP-1)-mediated over-expression of SATB1 is associated with nasopharyngeal carcinoma (NPC) progression, suggesting SATB1 may represent a promising biomarker and therapeutic target for NPC
We found that treatment of SATB1-expressing NPC cells with SATB1-specific Small interfering RNA (siRNA), attenuated cell proliferation and motility which verified by the changes of expression of Proliferating cell nuclear antigen (PCNA) (Figure 4), cell viability (Figure 5) and cell migration (Figure 6)
Summary
Special AT rich sequence binding protein 1 (SATB1) plays a crucial role in the biology of various types of human cancer. High expression of SATB1 has been linked to the progression of human gastric cancer [10,11,12], ovarian carcinoma [13], liver cancer [14,15,16], rectal cancer [17,18], laryngeal squamous cell carcinoma [19], cutaneous malignant melanoma [20], and prostate cancer [21,22]. In contrast to these reports, Selinger et al reported that loss of SATB1 is associated with poor prognosis in lung squamous cell carcinoma [23]. The role of SATB1 in tumorigenesis remains unclear and requires further investigation
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.